Ponicidin, an Ent-Kaurane Diterpenoid Derived from a Constituent of the Herbal Supplement PC-SPES, Rabdosia rubescens, Induces Apoptosis by Activation of Caspase-3 and Mitochondrial Events in Lung Cancer Cells In Vitro

REFERENCES

• Boon H., Wong J. Botanical medicine and cancer: a review of the safety and efficacy. Expert. Opin. Pharmacother. 2004; 5: 2485–2501, [CSA]
   PubMed Web of Science ®Google Scholar
• Kosty Michael P. PC-SPES: hope or hype?. J Clin. Oncol. 2004; 22: 3657–3659, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Darzynkiewicz Z., Traganos F., Wu J. M., Chen S. Chinese herbal mixture PC SPES in treatment of prostate cancer (review). Int. J. Oncol. 2000; 17: 729–736, [CSA]
   PubMed Web of Science ®Google Scholar
• de l a, Taille A., Hayek O. R., Burchardt M., Burchardt T., Katz A. E. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J. Altern. Complement. Med. 2000; 6: 449–451, [CSA]
   PubMed Web of Science ®Google Scholar
• Sartippour M. R., Seeram N. P., Heber D., Hardy M., Norris A., et al. Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int. J. Oncol. 2005; 26: 121–127, [CSA]
   PubMed Web of Science ®Google Scholar
• Han Q. B., Li R. T., Li M. L., Mou Y. K., Tian Q. E., Li S. W., Sun H. D. Ent-kauranoids from Isodon rubescens var. taihangensis. J. Asian. Nat. Prod. Res. 2005; 7: 31–36, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Li S. H., Niu X. M., Peng L. Y., Zhang H. J., Yao P., Sun H. D. Ent-Kaurane diterpenoids from the leaves of Isodon xerophilus. Planta Med. 2002; 68: 946–948, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Meade-Tollin L. C., Wijeratne E. M., Cooper D., Guild M., Jon E., et al. Oridonin and ponicidin are responsible for the antiangiogenic activity of Rabdosia rubescens, a constituent of the herbal supplement PC SPES. J. Nat. Prod. 2004; 67: 2–4, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Han Q. B., Li M. L., Li S. H., Mou Y. K., Lin Z. W., Sun H. D. Ent-kaurane diterpenoids from Isodon rubescens var. lushanensis. Chem. Pharm. Bull. 2003; 51: 790–793, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hayashi K., Hayashi T., Sun H. D., Takeda Y. Contribution of a combination of ponicidin and acyclovir/ganciclovir to the antitumor efficacy of the herpes simplex virus thymidine kinase gene therapy system. Hum. Gene. Ther. 2002; 13: 415–423, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liu J. J., Huang R. W., Lin D. J., et al. Antiproliferation effects of ponicidin on human myeloid leukemia cells in vitro. Oncol. Rep. 2005; 13: 653–657, [CSA]
   PubMed Web of Science ®Google Scholar
• Rossi D., Gaidano G. Messengers of cell death: apoptotic signaling in health and disease. Haematologica 2003; 88: 212–218, [CSA]
   PubMed Web of Science ®Google Scholar
• Tsuruo T., Naito M., Tomida A., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003; 94: 15–21, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Debatin K. M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunol. Immunother. 2004; 53: 153–197, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kirkin V., Joos S., Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 2004; 1644: 229–249, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Manion M. K., Hockenbery D. M. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol. Ther. 2003; 2(4)S105–S114, Suppl 1[CSA]
   PubMed Web of Science ®Google Scholar
• Kim R., Tanabe K., Uchida Y., Emi M., Inoue H., Toge T. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. the contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol. 2002; 50: 343–352, [CSA]
   PubMed Web of Science ®Google Scholar
• Smolewski P., Darzynkiewicz Z., Robak T. Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications. Leuk. Lymph. 2003; 44: 1089–1104, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zimmermann F. B., Molls M., Jeremic B. Treatment of recurrent disease in lung cancer. Semin. Surg. Oncol. 2003; 21: 122–127, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Chiyo M., Sekine Y., Iwata T., Tatsumi K., Yasufuku K., et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J. Thorac. Cardiovasc. Surg. 2003; 126: 1141–1146, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kelsen D. Chemotherapy of esophageal cancer. Semin. Oncol. 1984; 11: 159–164, [CSA]
   PubMed Web of Science ®Google Scholar
• Liu J. J., Wu X. Y., Peng J., et al. Antiproliferation effects of oridonin on HL-60 cells. Ann. Hematol 2004; 83: 691–695, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Liu J. J., Huang R. W., Lin D. J., et al. Anti-proliferative effects of oridonin on SPC-A-1 cells and its mechanism of action. J. Int. Med. Res. 2004; 32: 617–625, [CSA]
   PubMed Web of Science ®Google Scholar
• Badran A., Yoshida A., Ishikawa K., Goi T., Yamaguchi A., et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem. Biophys. Res. Commun. 2004; 314: 902–907, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Escuin D., Rosell R. The anti-apoptosis survivin gene and its role in human cancer: anoverview. Clin. Lung Cancer 1999; 1: 138–143, [CSA]
   PubMedGoogle Scholar
• Falleni M., Pellegrini C., Marchetti A., Oprandi B., Buttitta F., et al. Survivin gene expression in early-stage non-small cell lung cancer. J. Pathol. 2003; 200: 620–626, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ikehara M., Oshita F., Kameda Y., Ito H., Ohgane N., et al. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol. Rep. 2002; 9: 835–838, [CSA]
   PubMed Web of Science ®Google Scholar
• Chao J. I., Kuo P. C., Hsu T. S. Down-regulation of survivin in nitric oxide-induced cell growth inhibition and apoptosis of the human lung carcinoma cells. J. Biol. Chem. 2004; 279: 20267–20276, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lu B., Mu Y., Cao C., Zeng F., Schneider S., et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004; 64: 2840–2845, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Suzuki A., Ito T., Kawano H., Hayashida M., Hayasaki Y., et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene 2000; 19: 1346–1353, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lu C. D., Altieri D. C., Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998; 58: 1808–1812, [CSA]
   PubMed Web of Science ®Google Scholar
• Adida C., Berrebi D., Peuchmaur M., Reyes-Mugica M., Altieri D. C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998; 21: 882–883, [CSA], [CROSSREF]
   Google Scholar
• Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000; 6: 127–134, [CSA]
   PubMed Web of Science ®Google Scholar
• Kawasaki H., Altieri D. C., Lu C. D., Toyoda M., Tenjo T., Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998; 58: 5071–5074, [CSA]
   PubMed Web of Science ®Google Scholar